NDAORALSOLUTION
Approved
Jul 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
VOSTALLY (ramipril) by Teva is angiotensin-converting enzyme inhibitors [moa]. First approved in 2025.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSTALLY is an oral solution formulation of ramipril, an ACE inhibitor approved by the FDA on July 23, 2025. It treats hypertension and heart failure by inhibiting angiotensin-converting enzyme, reducing angiotensin II production and lowering blood pressure. This is a generic reformulation entering a mature market with established efficacy and safety.
Growth12.9 years to LOE
Early-stage growth product with 12.9 years of patent protection; commercial infrastructure and sales teams are being built to establish market presence in a competitive ACE inhibitor category.
Mechanism of Action
Angiotensin-converting Enzyme Inhibitors
Pharmacologic Class:
Angiotensin Converting Enzyme Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
Started Oct 2023
266 enrolled
Hypertension
Ramipril for the Treatment of COVID-19
Started May 2020
160 enrolled
COVID-19
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Started Jun 2019
295 enrolled
Myocardial Infarction
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
Started Jan 2018
16 enrolled
Diabetes MellitusHealthy Subjects
Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy
Started Mar 2016
528 enrolled
Hypertension
Worked on VOSTALLY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.